Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Br J Dermatol, 2020.
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group.
Read publication: Br J Dermatol
Related
Characteristics of "super responders" and "super nonresponders" to first biologic monotherapy for ps...
Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoria...
Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation stu...
Contact Us
Find Us
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester
M15 6GZ
0 Comments